Latest posts
-
Alembic seeks to mix it with US and European players
Alembic seeks to mix it with US and European players Indian pharmaceutical firm Alembic is seeking to expand its presence in the lucrative US and European drug markets through an expanded partnering programme. The Gujarat-headquartered group, which is involved in both the active pharmaceutical ingredient (API) and pharmaceutical formulation markets, aims to grow internationally and
-
Green Initiatives in India: Sustainable Pharma Manufacturing
GREEN INITIATIVES IN INDIA: Sustainable Practices in Pharma Manufacturing In an age where environmental concerns are at the forefront of global discussions, every industry must take responsibility for its carbon footprint. The pharmaceutical manufacturing sector, in particular, has been under scrutiny for its environmental impact due to energy-intensive processes and waste generation. However, the industry
-
Dr Reddy’s in collaboration with SkyePharma on delivery system
Dr Reddy’s in collaboration with SkyePharma on delivery system Using two of SkyePharma’s unique drug delivery systems, the UK company SkyePharma has agreed to conduct a feasibility study on an unnamed product with Dr Reddy’s Laboratories of India. The study’s expenses will be covered by Dr. Reddy’s, and SkyePharma will also get a “small” up-front
-
Competition intensifying for diabetes subjects; Acurian
Competition intensifying for diabetes subjects; Acurian Acurian, a company that specializes in patient recruiting, has reached a significant business milestone with the addition of more than 50 percent of the country’s type 2 diabetes population to its database. Approximately 8 million of the estimated 16 million diagnosed type 2 or adult-onset diabetes are already on
-
FDA lists drugs with potential safety issues
FDA lists drugs with potential safety issues A list of drugs currently being evaluated for potential safety issues by the US Food and Drug Administration (FDA) has been posted on its website. The list has been published under laws brought in last September that require the FDA to inform the public of new safety information or potential
-
Sandoz boosts Canadian production capacity
Sandoz boosts Canadian production capacity Sandoz Canada, a unit of Novartis’ generics arm, has opened a second manufacturing plant at its site in Boucherville, Quebec, boosting local production capacity 66 per cent. The plant, which is due to be fully operational by mid September, comprises manufacturing, laboratory and warehousing space that the firm believes will
-
Cholesterol- lowering drug given cancer all-clear
Cholesterol- lowering drug given cancer all-clear Cancer fears about a cholesterol- lowering drug have turned out to be a ‘statistical blip’. A class of cholesterol- lowering drug that had been implicated in a cancer scare has been cleared by epidemiologists using the results from two large ongoing clinical trials. Preliminary results from the relatively small
-
Big pharma’s pre-competitive collaboration
Big pharma’s pre-competitive collaboration Merck, Eli Lilly and Pfizer have provided funding to launch Enlight Biosciences, a for-profit venture that aims to advance breakthrough technologies for drug discovery and development. The lowdown: There has recently been increasing emphasis from industry on participating in non-profit collaborations to address issues in drug development that are considered to